January 7-9, 2013 The Sir Francis Drake Hotel,

Union Square, San Francisco, CA

6TH ANNUAL ONEMEDFORUMProfiting from Disruptive Changes

in Healthcare and Finance

We are excited to present our 6th Annual OneMedForum. We have some exceptional panels, programming and participating companies alongside a new connecting vehicle. OneMedPlace Connect is a very powerful new partnering system we have put in place to help those building growth companies meet the right people easier. We are also introducing a new Investment Platform that capitalizes on the important developments with the JOBS Act. The JOBS Act as a source of hope? Venture capital is on its death bed, IPO’s are out. Banks do not lend. So where do growth companies find the investment capital? We anticipate the JOBS Act -- with Crowdfunding and the capacity for private companies to solicit investors generally – can along with changing demographics foster a period of growth. The OneMedPlace Global Investment Platform will combine investment research and investment opportunities in the Healthcare sector. We are surveying CEO’s of growth companies to ask them what research they respect most in their area of expertise and where they would invest (other than in their own company). We think this could give us great insights where the smart money is going. China Forum III. On Monday afternoon, January 7th, we will once again run our popular China Forum. China represents a significant opportunity for almost any company with a useful healthcare product or service. If an EGC can find the right partner and structure the right deal, this emerging market can be a source of capital and ongoing income, as China is hungry for Western technology. China Forum III will focus how to structure a deal that works. See information on page 25. Thanks to our Sponsors, we are able to offer workshops and important panel sessions. We have available to you a wealth of talent and some of the most respected names in our industry. Let us know what you are looking for and we can help connect you. Also note that OneMedTV will be covering the event. If you can’t attend, we will be webcasting live public company presentations and capturing the wealth of content assembled. Just check in at OneMedPlace.com. We hope to see you in San Francisco.

THANKS TO OUR SPONSORS:

3

JOBS Act: Impact on Financing Growth CompaniesChanges to General Solicitation (under Reg. D) will have a dramatic impact on how private companies can use the internet to raise capital. A look at how companies and investors can benefit from this envrionment.

Wednesday, January 9thTuesday, January 8th

Connected Health: The Digital Healthcare RevolutionThe rapid advances in communications technology is sweeping the healthcare sector and disrupting traditional business models. How can investors and companies frame capitalize on this new reality?

Diagnostics: The Death of Reactive MedicineThe development of biomarkers and the perfection of genome sequencing is beginning a new era in personalized medicine. How can financiers find and evaluate the range of investment opportunities?

Crowdfunding: Can it Play a Role in EGC Financing?Crowdfunding is a new dynamic that enables average investors to become venture capitalists and gamble on new companies. What role will it play in incubating new technologies?

Bootstrapping Finance: Medical Device DevelopmentIn an economy in which capital is tight, medical device developers are using innovative approaches to staged development, overseas source channels and creative regulatory to reach market with less resources.

Tech Transfer: Universities as Competitive AdvantageWhat are the new approaches to tapping the intellectual property at US universities? How can investors and EGCs leverage this powerful asset to gain outsized returns and competitive advantage?

OneMedForumSF VI Table of Contents

Special Session: CEOs UnpluggedIndustry leaders and company executives discuss the outlook for 2013, produced by AdvaMed 2013.

Special Session: Fund Managers UnpluggedIndustry growth perspective from the most successful investors in microcap healthcare and life sciences.

Presenting Companies Include:

AcuityBioAdvaxis ADVENTRX Pharmaceuticals Agenus Bio Amarantus Biosciences Angel Medical SystemsAsuragen Atossa Genetics Bacterin International Becker Smith MedicalBioLife Solutions Biomay CardioCommCellAegis Devices ClinovaCognoptixColby Pharmaceuticals Colibri TechnologiesCollabRX Convergent Medical SystemsCorinnova Custom ArrayCytoSorbents DARA Biosciences Discogen Domain Surgical EchoguideEllman International Emmaus Medical EndoSphere

EndurxEnteRomeEpiomed TherapeuticsEpion Health ETView Medical ExThera Medical Fibrocell ScienceFluoroPharma Glysure Histogenics HistosonicsImmune Pharmaceuticals ImmunoVaccine Tech. Implandata Opthalmic Products InfoBionicInnara Health Innova Medical Design IntelGenx Interface BiologicsInvion IR2Dx ISTO Technologies iTi Health MEDomics Mercator MedSystemsMetabiomicsMicro Interventional Devices MiMedx Group Miracor Medical Monteris Medical

Nanoviricides Native CardiovascularNeoControl NeuroMetrix OragenicsOxygen BiotherapeuticsPressure Biosciences Radisens DiagnosticsResponse Biomedical Corp.Ridge Diagnostics S.E.A. Medical SystemsSalvetisSoft Tissue Regeneration Stroma Medical Corporation Synthetic Biologics Targeted Medical Pharma Tensys MedicalTianyin Pharmaceuticals (TPI)Tissue Regeneration SystemsTNI BiotechUE Life SciencesVaccinogenVertiflex

Monday, January 7th: China Forum III.

4

New for OneMedForum 2013 is our advanced partnering program.In just a few minutes you can complete a profile and schedule to meet any of the other registered attendees at any time you like.

Our partnering system merges the basic tools for attendees to create meetings with the latest smart phone technology to create a platform to provide an all-encompassing virtual networking experience.

OneMedPlace Connect incorporates individuals’ profiles, complete with pictures and background, as well as status updates and real-time schedule. OneMedPlace Connect is a downloadable app, and will feature the virtual conference book for your convenience.

Visit OneMedPlace Connect and fill out your profile. Do not hesitate to contact our Partnering Coordinator, Donna Williamson (dwilliamson@onemedplace.com) for assistance.

Partnering / Meeting space is being made available throughout the conference

Monday January 7th Mezzanine Level From 12pm to 5pm

Tuesday & Wednesday 2nd Floor Empire Room From 8am to 5pm (except during lunch)

In April 2012 the most significant US securities regulation in almost 80 years was signed into law. The JOBS Act (Jumpstart Our Business Startups) was passed to help small companies access investment capital to grow, innovate and create jobs.

Under the new law companies are no longer prohibited from “generally soliciting” investors with whom they don’t already have an existing relationship. This significant change will broaden the opportunities for companies to reach investors.

In response to this historic development, OneMedPlace is introducing its Global Investment Platform which will aggregate invesment research and investment opportunities via its focused portals.

The Platform will give investors strategic guidance and acccess to a wealth of insight from investment research and analysis from the OneMedPlace content library, as well as from our network of leading research and content providers and profiles of promising companies.

Introducing the Global Investment Platform global

Investment Platform

The most promising investmentopportunities in health and medicine.Now available to investors worldwide.

“The rescission of the prohibitionagainst general solicitation underRegulation D of the Securities Actis perhaps the most signifcant change to US securities in generations. It could dramatically improve the ability of growth companies to access capital.”

To receive more information of a demonstration Contact Brad Morgan. bmorgan@onemedplace.com.

David Weild IV, former vice chairman of Nasdaq

Using the Platform investors can access investment research and see standard profiles of investment opportunities.

6

In an era of increased financial regulation such as Dodd-Frank, Congress quickly passed The JOBS Act in April of this year in response to a need to increase the flow of capital to job creating entrepreneurs. Some argue that the most important and far reaching component of the JOBS Act was the removal of the ban on General Solicitation,which for 80 years has prohibited companies to solicit investors outside a pre-existing relationship. A panel of experts will discuss these opportunities and issues. Note: At the time the panel assembles the final regulatory issues should be in place. Such questions include:

• How will the SEC regulate the the services assisting in general solicitation?• How will investment banking be affected, and how will this group respond?• What are the best strategies and campaigns for companies to tell their story?

David Weild IV (Moderator)Grant Thornton Mr. Weild was former vice Chairman of NASDAQ and head of equity markets at Prudential where he priced over 500 IPOÂ’s and another 500 follow-on offerings. He invented the underwritten

“Registered Direct” and “Accelerated Book Build” offering – a form of equity finance for public companies that protects the issuer’s stock price from short sellers.

Gregory C. SimonCEO, PoliwoggHas held senior positions in both houses of Congress and the White House, been a senior strategy consultant to a number of international technology CEOs, led a national patient advocacy nonprofit he co-founded with Mike Milken, and has served as a senior executive at a large pharmaceutical corporation.

Robert PuopoloShareholder, Greenberg Traurig LLP Corporate & Securities Practice GroupSpecializes in corporate and securities law representing public and privately held companies in a variety of life science, clean technology and technology industries, as well as the venture capital and private equity firms and investment banks that focus on these companies.

Greg BroggerFounder & President,SharesPost, Inc.Specializes in corporate and securities law representing public and privately held companies in a variety of life science, clean technology and technology industries, as well as the venture capital and private equity firms and investment banks that focus on these companies.

6th Annual OneMedForumPanels

Changes to Reg D. General Solicitation: The Dramatic Catalyst of the JOBS Act.

Tuesday, January 8th8:00AM- 8:50AM

7

Experts predict that in the future computer chips implanted in a patient’s body will provide a means to monitor health and prevent disease. As such information as a patient’s blood sugar levels or heart rate is tracked and delivered to your provider (and tracked by your payor) patients can receive real time adjustments to medication delivery systems implanted in their body. This panel will look at how investors and entrepreneurs can begin to frame their strategic thinking to capitalize on this new reality.

• How can investors assess the impact that these trends have on their current and future portfolio companies?• What is the regulatory path for these technologies?• Why is there a need for a med-cloud?• How is ‘big healthcare’ approaching the sector?• Will there be insurance and reimbursement precedents?

Peter NeupertOperating Partner, Growth Buyout Fund, Health Evolution PartnersServed as the founding President and Chief Executive Officer of drugstore.com. Also served as Corporate Vice President of the Microsoft Health Solutions Group, responsible for driving the company’s strategy to improve healthcare around the world through software innovation. He took drugstore.com public in 1999 and led drugstore.com to become a top online retail store and information site for health and wellness.

Jack YoungDirector, Qualcomm Life Fund, Qualcomm VenturesHeads up the $100M Qualcomm Life Fund (QLF) at Qualcomm Ventures. His investment interest is focused on the emerging wireless health space including wellness and fitness, chronic disease care, remote diagnosis and monitoring, healing and aging in place, health informatics, etc. Jack currently serves as a board observer at QLF portfolio companies including Airstrip, AliveCor and Telcare.

Kyra Bobinet, M.D.Head of Senior Care Solutions, Emerging Businesses, AetnaIIts within Aetna’s new business incubator, Emerging Businesses, as the Head of Senior Care Solutions. In this role, Dr. Bobinet is building a start-up suite of technology-based consumer products and services that can address the growing need for seniors to prolong their independence, quality of life and social connectivity.investment banks that focus on these companies.

Andrew Colbert (Moderator) Senior Vice PresidentZieglerAndrew Colbert joined the corporate finance team at Ziegler in 2006. He specializes in advising healthcare services and healthcare information technology companies on a spectrum of strategic and financing alternatives including mergers and acquisitions, capital raising transactions and partnership development.

Connected Health.Technology in the Hands of Patients Changes Health Delivery. A Brave New World of Medicine.

Wednesday, January 9th10:20AM- 11:10AM

Dirk Lammerts, M.D.Managing Director Digital Health, Burrill & CompanyThroughout his career, Dirk has been driving technology convergence through innovative use of computer technologies and online, mobile, and interactive media in medicine, based on the premise that these technologies are providing a platform to fundamentally improve access to and quality of healthcare worldwide. He worked as a consultant for McKinsey & Company, as Vice President Molecular Diagnostics at Affymetrix and as Vice President Marketing and Corporate Development at XDx. Dirk serves on the Board of Directors of AliveCor.

8

Where it converges with therapeutics, diagnostics is seeing the beginning of a new era. Exciting advances are being made in the development of biomarkers for clinical use beyond the research setting. Regulatory bodies including the FDA are increasingly receptive to trial designs incorporating companion diagnostics. Next-gen sequencing takes the industry to new heights of the enabling technologies, which fuel the growth of personalized medicine.This panel will discuss the rapid technological advances in diagnostics and personalized medicine, and the challenges and opportunities facing the industry.

• What effect will Prometheus v. Mayo Clinic and similar cases have on patent protection in the biomarker space?• How will companies navigate the regulatory path?• What is the market opportunity in genome sequencing?• When will the cost be non-prohibitive?• How does this sector brace for the inevitable paradigm shift?

Phil Dehazya, PhD (Moderator)Program Director, Oncology, Aptiv SolutionsPromotes the understanding of biomarkers and advanced techniques among the staff and helps to advance the use of adaptive clinical trial methodology among clients. Phil assists business development efforts in the areas of new client proposals, data gathering and mining, training staff for new assignments in oncology, undertakes consulting projects and provides project management support when needed.

Charles M. Fleischman Executive Director, Institute for Health Technology StudiesIs an entrepreneur and venture capitalist. He has recently served as a Director on the Boards of One Lambda, Inc. (now Thermo Fisher Scientific) and Dako (now Agilent Technologies). He is also a member of the National Advisory Council, Johns Hopkins University School of Education. Mr. Fleischman held multiple positions at Digene Corporation from 1990 to 2006, including President, Chief Financial Officer, Chief Operating Officer, and Director

William QuirkManaging Director and Senior Research Analyst, Piper JaffrayIs focusing on the medical diagnostics and life science tools sectors. Prior to joining Piper Jaffray in 2006, Quirk worked in equity research at RBC Capital Markets in Minneapolis and at Paine Webber in New York. In 2012, he was named the 2012 most accurate earnings forecaster for the Life Science Tools industry by Starmine.

Diagnostics. Genome Sequencing, Biomarkers, and the Death of Reactive Medicine.

Tuesday, January 8th1:30PM- 2:10PM

Andrew I. McDonaldCo-Founder,LifeSci AdvisorsInvestment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales. Previously served as senior biotechnology analyst at Great Point Partners. From 2004-2006, was co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners.

9

OneMedForum is pleased to again offer one of AdvaMed’s signature CEOs Unplugged sessions. These leaders in the medical technology sector will address some of the industry’s most critical issues, such as the Medical Device User Fee Act, key innovations in diagnostics, developments in venture and capital markets, and the widely debated medical device excise tax. Attendees can expect to gain a deep understanding of the industry’s most pressing challenges and opportunities.

Stephen J. Ubl (Moderator)President and CEO of AdvaMedThe world’s largest medical technology association. Mr. Ubl is recognized as a top health care advocate and policy expert across multiple health policy sectors, having successfully worked with medical technology manufacturers, hospitals, patient groups, physicians and public and private payers. His lobbying accomplishments include passing landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies.

David DvorakPresident and Chief Executive Officer, and a member of the Board of Directors, ZimmerDavid Dvorak was appointed President and Chief Executive Officer and a member of the Board of Directors on May 1, 2007. Mr. Dvorak joined Zimmer in December 2001 shortly following the spin-off from Bristol-Myers Squibb. Prior to joining Zimmer, he was Senior Vice President, General Counsel and Secretary for STERIS Corporation, an Ohio-based leader in medical products sterilization and contamination prevention products and services.

Virginia S. RybskiPresident, Chief Executive Officer and Director at RegenesisDuring her tenure with Regenesis, Ms. Rybski has held several positions including Chief Operating Officer, Vice President of Sales and Marketing, and Vice President of Corporate Development. She has combined 35 years of experience founding, building and growing emerging bioscience companies by developing and launching numerous advanced-technology, healthcare related products.

Peer M. SchatzManaging Director, Chief Executive Officer, QIAGENHas spearheaded the development of QIAGEN’s strategic focus on sample and assay technologies and the efforts to bring these technologies to customers in molecular diagnostics, applied testing, academia and the pharmaceutical industry. Mr. Schatz joined QIAGEN in 1993, under his direction, QIAGEN has grown to employ more than 3,800 people in over 35 locations around the world and boasts revenues of more than US$ 1 billion.

CEOs Unplugged.Up Close with theIndustry’s Most Respected Names.

Tuesday, January 8th4:30PM- 5:15PM

Special Session

10

The component of the JOBS Act that got the most attention was Crowdfunding. It allows for the first time companies to aggregate investors in early stage companies on the Internet portals. Created to increase the flow of capital, it creates an entirely new dynamic that enables average investors become venture capitalists and gamble on new companies. The final rules and regulatory elements are being drafted by the SEC and are expected by year end. Experts will explore the key issues:

• How will crowdfunding portals work? How will these portals be regulated?• Can a crowdfunding strategy be used by existing companies?• How does such a strategy fit within overall financing programs?• Will later-stage investors and larger investors embrace companies that have

Aftab Jamil (Moderator) Technology and Life Sciences Practice Leader, BDOOver 22 years of experience in public accounting, substantial experience in serving life sciences companies. Has served public and private companies ranging from start-up, development stage VC backed enterprises to multi-billion dollars international companies. He has participated in the preparation of numerous IPOs and secondary public equity and debt registration statement filings as well as on-going Securities and Exchange Commission reporting.

Steve SalmonGeneral Partner, Latterell Venture PartnersIs a seasoned medical device professional bringing over 20 years of product development and management experience to LVP. Steve has held several executive and R&D management positions within both large public medical device companies and small medical device startups, including Engineering Manager with CVIS, VP R&D with Boston Scientific, Co-Founder and VP Operations of Integrated Vascular Systems, and Co-Founder of Ensure Medical.

David AllenPartner, K&L Gates LLPMr. Allen’s practice focuses on capital markets, mergers and acquisitions, and general corporate and securities matters including early stage company development across a variety of industries, including medical device, pharmaceutical, biotech and technology companies. In his capital markets practice, Mr. Allen has represented underwriters, issuers and investors in public offerings and private placements of debt, equity, and convertible securities. In the mergers and acquisitions area, Mr. Allen has represented acquirers, targets, financial advisors and special committees in a wide variety of transactions involving both public and private companies.

Crowdfunding in Healthcare.What is the Role of Crowdfunding in the Continuum of Financing Early Stage Innovation?

Wednesday, January 9th8:00AM- 8:50AM

Roham GharegozlouPartner, Rising Tide FundBased in San Francisco, Roham is an entrepreneur, angel investor, and partner at Rising Tide Fund, an early-stage venture capital firm. Prior to joining Rising Tide, Roham served with Newbury Ventures, a technology-focused venture fund with $300M invested capital in various verticals including mobile, enterprise, and life science technologies. He is a founder of Axiom Zen, and a director of its Launch Labs division focused on helping startups build better technology. Since 2009, he has served as Program Director with TechWadi, a Silicon Valley-based nonprofit.

11

In an environment where the costs increase while access to venture capital decreases, founders and investors in new companies must make due with less capital. This new reality requires strategies to get more done with less. This panel will look at how companies can leverage globalization, strategic partnering, modular development bring their technologies to market at a fraction of the traditional cost. It will examine managing the regulatory the opportunity to commercialize in international markets with far more ease. This session will explore major themes of bootstrapping and non-traditional approaches to building a business with limited resources, asking:

• How do companies ensure proper regulatory compliance ‘on the cheap’?• How has the regulatory pathway fostered this paradigm shift?• How does one evaluate the true cost of device development?

Christian Haller, Vice President, Product Development, MPR Associates, Inc. (Moderator)MPR Associates, Inc., is a trusted advisor and strategist for business executives in the medical technology and consumer products industries. Mr. Haller works with executives at start-ups and Fortune 500 companies to conceive, finance, develop, manufacture and market first of a kind products and new technologies. Mr. Haller is also a serial internal entrepreneur at MPR, where he has successfully built three new business units.

Thom RaschePartner, Earlybird VenturesIs a seasoned executive in the medical device and diagnostic sectors with over 21 years of operational experience. Since he joined Germany's Earlybird, Thom has been responsible for the medical device portfolio and for making new investments in this area. He has successfully led various financing rounds in both European and US based companies including Calypso Medical Technologies, Inc. (Seattle, WA) and Zonare Medical Systems, Inc. (CA).

Vicki AnastasiSenior Vice President, Medical Devices,Aptiv SolutionsProvides business development leadership to create and foster priority relationships in the medical device and diagnostic marketplace, developing customized programs to meet medical device client needs. Previously, Vicki oversaw all activities of the Medical Device Regulatory services group, which provides strategic consulting and submission preparation, review and postmarket compliance support to U.S. and international clients.

Medical Devices. Bringing a Device to Market with Limited Resources.

Wednesday, January 9th10:20AM- 11:10AM

Ashley WallinVice President, Emerging Growth Company Council, Advanced Medical Technology Association (AdvaMed) In this role, Ms. Wallin represents the interests of the Association’s emerging and early-growth enterprises and focuses on facilitating a policy environment conducive to capital formation and innovation, advocating for domestic and international payment and regulatory policies that are favorable to emerging companies, and providing educational opportunities for industry leaders and professionals in this entrepreneurial sector.

12

A tremendous amount of medical and life science technology resides in US Universities which house products and technologies that could create new companies or greatly enhance existing company’s competitiveness. Increasingly industry and academia are collaborating more to capitalize on this asset. How can investors and entrepreneurs readily access these opportunities efficiently? What are the challenges? This panel will explore how to best access this underutilized asset:

• What are the most powerful tech transfer services? How is this number growing?• What are the best strategies to secure IP protection?• What are the best strategies to secure licensing?• How can newly spun out technologies obtain capital?

K. Lance Anderson, Council, Greenberg Traurig LLPFocuses his practice on intellectual property transactions. He has wide-ranging experience in licensing and transactional matters, including IP due diligence for in-licensing, mergers and acquisitions, patent brokerage, strategic planning, patent prosecution, patent litigation, and trade secrets. Lance previously served as the Director of the technology transfer and intellectual property office for the Texas Tech University System, as well as in-house counsel for Emergent Technologies, Inc.

Elias CaroVP— Technology DevelopmentWallace H. Coulter FoundationMr. Caro is VP of Technology Development in charge of the grant programs in biomedical research at the Wallace H. Coulter Foundation where he joined in 2006. From 1998 to 2006 in Beckman Coulter, he occupied positions ofincreasing responsibility as Vice President of Diagnostic R&D, President of the Biomedical Research Division and Executive Vice President in charge of International Diagnostics Commercial Operations and Worldwide Life Sciences.

Martin LehrAssociate, Osage University PartnersJoined Osage University Partners in 2009 and focuses on novel biopharmaceutical products, medical devices, diagnostics, and research tools. Prior to joining Osage, Martin conducted research in the areas of DNA repair at the Sloan-Kettering Institute and in thrombin activation at the Children’s Hospital of Philadelphia. Is on the Advisory Board of the Sid Martin Biotech Incubator at the University of Florida, is an advisor to the University City Science Center’s QED Program, and a mentor to the University of Pennsylvania’s Life Science Management program.

Paul Yock, M.D.Founding Co-Chair of Stanford’s new Department of BioengineeringIs internationally known for his work in inventing, developing and testing new devices, including the Rapid Exchange ™ balloon angioplasty system, which is now the primary system in use worldwide. He also invented a Doppler-guided access system known as the Smart Needle™ and PD-Access™. The main focus of Dr. Yock’s research program has been in the field of intravascular ultrasound. He authored the fundamental patents for mechanical intravascular ultrasound imaging and helped conduct the initial clinical trials.

Tech Transfer.Tapping into University Technology forBreakthroughs and Competitive Advantage.

Wednesday, January 9th 1:30PM- 2:10PM

13

Are the turbulent markets changes and challenges facing healthcare investors today part of a business cycle, or do they represent more fundamental changes? We have assembled veteran fund managers with exceptional long term successful track records investing in emerging growth companies in healthcare and the life science to offer their insights perspective for investors and entrepreneurs. Some of the topics:

• Does Obamacare matter? What does the expanding role of government mean for investment strategy?• How does the empowered consumer and changing dynamics of health delivery change investment opportunity?• What are the most long term and most promising fundamental long term investments themes?

Jeffrey J. Kraws (Moderator)CEO and co-founder ofCrystal Research AssociatesIs well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry (see Awards section). Prior to founding the Company, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, served as a managing director of healthcare research for Ryan Beck & Co., and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC .

Dennis J. PurcellSenior Managing Partner, Aisling CapitalHas served as the Senior Managing Director of Aisling Capital since February 2000 and is responsible for the management of the Partnership. The fund has approximately $1.7 Billion of assets under management. Prior to joining Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years.

J. Misha PetkevichCo-Founder, Bladerock CapitalPrior to co-founding BladeRock Capital, Misha was Chairman and Chief Executive Officer of The Petkevich Group, LLC, a small merchant bank focused on providing specialized services to and executing transactions for life science, information technology, and consumer related emerging growth companies. Before founding The Petkevich Group, Dr. Petkevich was a Managing Director and Head of Investment Banking at Robertson Stephens & Co.

Fund Managers Unplugged.Veteran Healthcare Fund Managers Outlook on 2013 and Beyond.

Wednesday, January 9th4:00PM- 4:50PM

Special Session

William S. Slattery Partner, Deerfield ManagementMr. Slattery has served at the firm since 2000. Mr. Slattery’s primary responsibility includes biotechnology investments. From 1992 to 1999, he was the Senior Healthcare Analyst at Amerindo Investment Advisors, Inc., also specializing in biotechnology and health information technology. Prior to 1992, Mr. Slattery held a variety of research and administrative positions in clinical development and alternative care settings.

14

● ACUITYBIO Privately-held company based in the Greater Boston area, formed in late 2008 to commercialize novel polymer drug delivery technologies to treat various types early stage, soft tissue cancers. AcuityBio's lead product candidate is aimed at preventing the recurrence of non-small cell lung cancer is based on a synthetic polymer technology.Management: Mark Grinstaff, Co-founder; Jesse Wolinsky, Director of Research and Development

● ADVAXIS / (ADXS)Biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based upon a novel platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bio-engineered to secrete an antigen/adjuvant fusion (Lm-LLO) protein. Management: Thomas A. Moore, Chairman, CEO; Mark Rosenblum, CFO

● ADVENTRX PHARMACEUTICALS / (ANX)San Diego-based biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. ADVENTRX is initially developing ANX-188 as a treatment for complications arising from sickle cell disease.Management: Brian M. Culley, CEO; Santosh Vetticaden, CMO; Patrick Keran, President & COO

● AGENUS BIO / (AGEN)Agenus Inc. (Nasdaq: AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic. Between Agenus and its partners, 19 programs are in clinical development. Agenus’ QS-21 Stimulon® adjuvant is being studied in clinical trials for 17 vaccine indications. They include four Phase 3 GSK programs: RTS,S for malaria, MAGE-A3 for non-small cell lung cancer and melanoma and Zoster Herpes for shingles. Agenus Phase 2 programs include: Prophage Series G-100 and G-200 for newly diagnosed and recurrent glioma and HerpV for genital herpes. Management: Garo H. Armen, Chairman and CEO

● AMARANTUS BIOSCIENCES / (AMBS)Developing a novel therapeutic protein that has neuron-protective properties – termed MANF – which has the potential to serve as a first-in-class treatment for neurological disorders that stops and/or reverses their debilitating effects. MANF is also significantly cardiac-protective, providing Amarantus the ability to employ a two pronged drug development approach – a neurological disorder platform, and a heart disease platform. Presenter: Gerald Commissiong. Management: Gerald E. Commissiong, President and CEO

Presenting Companies

Companies presenting at OneMedForum SF2013.

● ANGEL MEDICAL SYSTEMSDeveloped the AngelMed Guardian, the first implantable, patient alerting system designed for early detection and prevention of heart attacks. Time to treatment delays after a heart attack - of more than 3 hours - are primarily caused by patients who postpone calling for help, many times compounded by the fact that nearly 50% of victims have either atypical or no physical symptoms at all. This delay in treatment is the main cause of mortality and morbidity from heart attacks. The Guardian tracks changes in the heart’s electrical signal 24 hours a day, seven days a week and warns patients in advance of or at the first signs of a heart attack, as an emergency alarm is triggered prompting patients to seek immediate medical attention. The Guardian System will significantly reduce the time to treatment as well as the costs of care for heart attack patients, and is primarily intended for use in high risk survivors of a first heart attack. Management: David Fischell, CEO; Andrew Taylor, CFO

● ASURAGENAsuragen is a molecular diagnostics company with a pioneering position in miRNA using genomics to drive better patient management through best-in-class clinical testing solutions. Today, Asuragen’s products, services and technologies drive countless patient management decisions across oncology, genetic disease, and other molecular testing modalities.Management: Matt Winkler, CEO/CSO; Rolland Carlson, President

● ATOSSA GENETICS / (ATOS)Focused on novel cellular and molecular diagnostic risk assessment products for breast cancer. Using patented, FDA-cleared Mammary Aspirate Specimen Cytology Test (MASCT) System, a nurse or physician’s assistant, can painlessly collect a sample of Nipple Aspirate Fluid (NAF) in about 10 minutes, for cytological testing. The MASCT System is FDA cleared for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells. Management: Dr. Steven C. Quay, Chairman of the Board and CEO; Dr. Shu-Chih Chen, CSO

● BACTERIN INTERNATIONAL, INC. / (BONE)Develops anti-microbial, anti-infective coatings for revolutionary bone graft material and also processes and markets innovative, biologic allografts for transplantation. Objectives of allograft use include pain relief, aid in tissue regeneration, and aid in bone fusion in spinal and sports medicine procedures. Bacterin's products are divided into three main areas: biologic products, medical devices, and coating technologies. The biologic products focus on human allografts for transplantation, featuring: OsteoSponge, a 100% bone graft designed as an alternative to gels, putties and ill-fitting grafts; OsteoWrap; sports medicine allografts for ACL and PCL repairs and reconstruction as well as meniscal repair); traditional allografts and milled allografts. Management: Guy S. Cook, Chairman of the Board, CEO, President and CSO; John Gandolfo, CFO

● BECKER SMITH MEDICALMedical device company that designs, patents, and markets medical devices related to well-defined and demonstrated needs in neurosurgery. The founder and CEO, Jan Eckermann M.D., is a practicing neurosurgeon serving as the medical director / principal investigator in the clinic trials, and providing vision and leadership. President Don Kloos is presenting the venture at OneMedForum in San Francisco January 8, 2013. We have designed, prototyped, clinically tested, established insurance reimbursement pathway, and filed patents for the FlowSafe (TM), our first in a series of four products. The FlowSafe automatically controls and monitors the critical fluid drain rates required for lumbar drain in cranial and spinal surgery procedures, and replaces manual human monitoring. Clinical IRB-approved testing was so successful, the participating hospital changed policy to make FlowSafe a standard of care on all lumbar procedures. Management: Jan Eckermann, CEO

15

● BIOLIFE SOLUTIONS, INC. / (BLFS)Develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in regenerative medicine (cell therapy and tissue engineering), bio banking, and drug discovery. BioLife’s products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife’s enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. Management: Michael Rice, Chairman & CEO

● BIOMAYBiomay is a contract manufacturing organization (CMO) for GMP-grade recombinant proteins and plasmid DNA. Headquartered in Vienna, Austria, Biomay has manufactured recombinant biomolecules with microbial systems (E. coli, yeasts) for more than 20 years, and develops products for preventative and therapeutic vaccination against allergic diseases. Management: Rainer Henning, PhD, CEO; Karl Fister, CFO

● CARDIOCOMM SOLUTIONS / (EKG)Products are marketed as Global EKG Management System (GEMS™ and GlobalCardio™). CardioComm is ISO 13485 certified and its products have been cleared for sale in the United States, Canada and the European Union. The company's products are sold worldwide to hospitals, call centers and physician’s offices through a combination of its external distribution network and its North American based sales team. This technology enables the recording, transfer, viewing, analyzing and storing of electrocardiograms (EKGs) over a global virtual healthcare network by physicians for the diagnosis and management of cardiac patients. Management: Etienne Grima, CEO; Anatoly Langer, Chairman of the Board; Wendy Hsieh, CFO; Wade Barnes, CTO

● CELLAEGIS DEVICESBased in Toronto, Canada, is poised for EU market introduction, CE Mark, in parallel with a broad international clinical testing program of the company’s proprietary, automated, noninvasive autoRIC™ Device for Remote Ischemic Conditioning (RIC). AutoRIC provides 50% reduction of myocardium damage from MI, reduced long term MACE and mortality rates. Placed around the arm, CellAegis’ autoRIC Device allows for the first time, simple, consistent, reliable and cost-effective automation of RIC at the point of care. Management: Rocky Ganske, CEO; John Berton, Chairman

● CLINOVASpeciality pharma company focused on developing, manufacturing, licensing and marketing innovative consumer healthcare products. Clinova currently markets its products in the UK and the emerging markets of Asia, Africa and the MENA region. The leading brand of Clinova is O.R.S a soluble tablet form of the WHO Oral Rehydration Salts formulation and is currently selling in UK with significant international rollout to key markets planned over the course of 2013.Management: Gerard Gregg-Smith, Chairman; Charles Ebubedike, CEO

● COGNOPTIXDeveloping an in-office, drug/device diagnostic system designed as an aid in the early detection of Alzheimer’s Disease (AD). A ligand or contrast agent (drug) and software-controlled optical instrument (device) allows for noninvasive detection and assessment of AD by measuring the hallmark of AD, beta amyloid, in the supranuclear region of the lens of the eye. The ligand is easily administered to the eye as an ophthalmic ointment and a proprietary Fluorescent Ligand Scanning (FLS) instrument, provides an objective and quantitative measurement of beta amyloid in the patient’s lens.Management: Paul Hartung, President and CEO; Gerald D. Cagle, COO; Tom Trometer, CFO

● COLBY PHARMACEUTICALSColby is developing new oral or injectable small molecule signal transduction modulator drugs and immune modulator biopharmaceuticals for cancer, chronic inflammation, pain, infectious, neurodegenerative or metabolic diseases. Colby Pharmaceuticals is going after indications for very sick patients with no alternatives, i.e. metastatic melanomas, gliomas, acute myelogenous leukemias, prostate, renal or other carcinomas and cancer radio-chemo-therapy induced-mucositis. The Company's technology enables highly effectivecancer antigen vaccines using immune activators and vaccine adjuvantsdelivered via proprietary ILNI, Intra Lymph Node Immunization. Colby is building a portfolio of drugs and diagnostics through in-licensing deals (i.e. Juvaris BioTherapeutics and MannKind Corporation), M&A (Othera Pharmaceuticals) and proteomics-/genomics-driven in-house diagnostics and clinical drug product development.Management: David Zarling, CEO; Ken Narducy, CSO; Hirak Basu, CSO; Anne Vallerga, CFO, EVP

● COLIBRI TECHNOLOGIES, INC.Colibri is developing minimally invasive imaging technologies with broad clinical relevance. Colibri’s patented 3D imaging catheters will provide physicians with images of the cardiovascular and other organ systems not previously attainable. The 3D imaging catheters will initially be introduced to assist with cardiac procedures that could benefit from better imaging guidance options.Colibri Technologies is developing a suite of image guidance technologies to make modern medical procedures safer, faster, less expensive and more effective. Management: Brian Courtney, CEO; Amandeep Thind, CTO

● COLLABRX / (CLRX)Product-driven data analytics company that uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on genomics-based medicine, with specific insights from the nation’s top clinical experts. CollabRx’ scalable technology platform blends a cutting-edge medical science and research knowledgebase assembled and curated using artificial intelligence-based search tools and analytics with the insights of practicing clinicians and researchers. CollabRx medical and scientific content is organized in a knowledgebase that expresses the relationship between genetic profiles, other aspects of the medical record (e.g., stage, prior treatments), and therapy considerations including molecular diagnostics, medical tests, clinical trials, drugs, biologics, and other information relevant for treatment planning. Starting with the area of greatest need, advanced cancer, their products and applications inform and facilitate communications between Pathologists and Oncologists and between Oncologists and their patients. Management: Thomas Mika, Chairman, President & CEO

● CONVERGENT MEDICAL SYSTEMSUsing a face recognition-based algorithm, the largest and proprietary skin-image database, and augmented reality display, the company developed the first automated skin diagnosis system, the Lubax (TM). The company has obtained patent protection, developed a working prototype, regulatory strategy, and are poised to access a $550M worldwide market for skin screening, monitoring, and diagnosis. Convergent Medical Solutions is seeking the next round of funding to finish the ramp to commercialization.Management: David S. Rose, Founder, CEO; Tom Pace, President, COO

16

● CORINNOVAPrivate medical device company that has developed a breakthrough technological platform for the treatment of heart failure. CorInnova has developed the CardiacSTARTM. It is a minimally invasive, direct cardiac compression device that restores normal cardiac motion to the heart through the application of gentle pressure. The CardiacSTARTM will be the first heart assist device on the market that promotes healthy cardiac motion rather than simply increase blood flow. By promoting correct motion, the device also promotes heart recovery. Unlike prior direct cardiac compression devices, CorInnova's technology does not invert the curvature of the heart. Moreover, unlike other cardiac assist devices, CorInnova's device does not touch the blood, eliminating the risk of thrombosis, stroke, and bleeding, and making it non-obligatory. Management: William Altman, President & CEO; John Criscione, Co-Founder & CTO

● CUSTOMARRAYProvides instruments such as the B3™ Synthesizer that uses semiconductor arrays to rapidly synthesize DNA arrays “on chip”. Arrays can be synthesized automatically on the instrument using either the 4x2k™, 12k™, or 90k™ array chips. In situ synthesis on up to 32 arrays (for 4x2k format) or 8 arrays (for other formats) can be performed in under 24 hours. Arrays can be read either using standard fluorescence chip readers or can be read using electrochemical detection on the ElectraSense reader. CustomArray also offers extensive services using their platforms to measure gene expression, to measure microRNA expression, to identify aptamer sequences, to identify potent siRNA sequences against select targets in vitro and validate the function of these targets both in vitro and in vivo, to provide large pools of oligos for specific applications such as sequencing, as well as other services. Management: Brooke Anderson, COO

● CYTOSORBENTS / (CTSO)Critical care focused medical device company using blood purification to treat life threatening diseases commonly seen in the intensive care unit such as sepsis, burn injury, trauma, acute respiratory distress syndrome, pancreatitis and many others. Its flagship product, CytoSorb®, is approved in the European Union as a best-in-class, broad extracorporeal cytokine filter, to be used in clinical situations where cytokines are massively elevated. This “cytokine storm”, if left unabated, can drive uncontrolled severe inflammation, which then can lead to cell death and organ failure – the leading cause of death in the ICU. The ultimate goal of CytoSorb® is to prevent or treat organ failure, something which no other approved therapy addresses today, thereby improving clinical outcome and controlling spiraling critical care costs. The Company is the recent recipient of approximately $5M in contracts from DARPA and the US Army and holds 30 issued US patents. Management: Dr. Chan, CEO; Vincent Capponi, COO, Thomas Bocchino, CFO, Dr. Robert Bartlett, CMO

● DARA BIOSCIENCES / (DARA)DARA BioSciences is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA is led by a team of strong business leaders comprised of highly experienced and diverse healthcare professionals conducting innovative acquisitions and efficient product development with expertise in clinical development, operations, sales & marketing, strategic planning, and technical operations. DARA's structure results in success -- for patients as well as investors. DARA is as innovative as the therapies they develop and are committed to improving patients’ quality of life.Management: David J. Drutz, CEO & CMO; Christopher Clement, President & COO; David Tousley, Acting CFO

●DISCOGENTargets the biological processes associated with inflammation and degradation of the intervertebral disc through topical and minimally invasive strategies. Discogen devices and therapies will treat a wide variety of back pain disorders that effect an age-related population of over 6 million patients diagnosed with DBP annually. Currently Discogen is seeking an investment of 3 million (US) to fund the development of the Discogen Ultra-Sound Generator, Hydrogel Delivery System and pilot human clinical studies, in- coordination with Pharma and/or Strategic Partner. Discogen intends to follow regulatory path of 510(k) for both of its patented products Management: Peter A. Zahos, MD, CEO; Marvin A. Collin, VP of Development

●DOMAIN SURGICALMedical device company developing advanced thermal surgical technology for soft tissue cutting and coagulation. The FMwand ferromagnetic surgical technology was originally conceived in an effort to create a better alternative to existing energy-based surgical modalities. To date, the company has raised $13 million from the founder, grants, angels, and private venture investors, including BioStar Ventures. With these resources, the capital-efficient company has completed product development and safety certification, built production tooling, secured regulatory clearance, and launched the design award-winning FMwand product line in the U.S. Management: David J. McNally, Chairman of the Board, CMO; Phillip L. McStotts, CFO

● ECHOGUIDEDeveloping devices to help physicians place catheters accurately, safely, and quickly. The devices are self-contained, single use, battery-powered, easy to use, and can be used anywhere. Initial indications are for ventricular drain placement for treatment of hydrocephalus - increased intracranial pressure caused by excess cerebrospinal fluid. The device consists of a stylet with an ultrasound transducer at its tip and an ergonomic handle containing batteries, electronics and display. Initial markets are in neurosurgery.Management: Samuel Browd, Co-Founder; Pierre Mourad, Co-Founder

● ELLMAN INTERNATIONALServes the global aesthetic, multi-specialty surgical, dental and veterinary markets with a full complement of value-based advanced radiofrequency (RF) and laser products for precision surgical and aesthetic procedures. Founded in 1959, Ellman International, Inc., a New York based manufacturer of medical devices for surgical and aesthetic procedures, remains recognized today as a pioneer in the development of specialized radiofrequency technology for precision cutting, coagulating and tissue ablation in physician’s offices, clinics and surgical centers. Ellman provides a wide range of products that are used in the non-surgical and surgical aesthetic markets, general and specialized surgical markets, dental and veterinary medicine in over 65 countries. Management: Frank D'Amelio, CEO. Dr. Jon Garito, President; Joan L. Carter, Vice President

● EMMAUS MEDICALThe mission of Emmaus Medical is to improve the lives of people with rare disease by the discovery, development and commercialization of innovative and cost-effective medicines. Emmaus Medical’s lead candidate is a treatment for Sickle Cell Disease currently in Phase III clinical trials. The company's NutreStore® is indicated for the treatment of Short Bowel Syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone approved for this indication. The company works jointly with CellSeed, Inc. to develop regenerative corneal epithelial sheets in the United States, a technology called “Cell Sheet Engineering” that has restored the vision of patients with limbal stem cell deficiency in trials conducted in Europe. Management: Yutaka Niihara, MD, MPH, CEO; Peter Ludlum, Executive Vice President and CFO

17

● ENDOSPHEREPioneer of endoscopically-insertable medical technologies. Founded in 2006, EndoSphere has developed a broad IP portfolio including 29 issued and pending U.S. and international patents. The company’s flagship product, the SatiSphere™ System, is a non-invasive treatment for one of the world’s largest health issues: Metabolic Diseases including Obesity and Type II Diabetes. The SatiSphere device improves the regulation of appetite and satiety by using the body’s natural physiology – providing an incisionless, reversible, and repeatable solution. The device has received CE Mark regulatory approval in 31 countries. Management: James Mckinley, CEO; Kenneth Binmoeller, MD, CMO

● ENDURXNovel Targeted and “Killing” Cancer and Cardiovascular Treatment and Imaging Technology. EnduRx’s proprietary technology is a set of unique peptides targeting “vascular zip codes” to deliver a therapeutic or imaging payload. The technology is composed of three distinct systems that have demonstrated success in published studies: Cancer:

“self-amplifying” targeting and “killing” system and has proven effective in pre-clinical models of prostate cancer and breast cancer. This technology increases the therapeutic index of drugs by targeting the drug compound directly to the tumor site. Cardiovascular: This system can be used in the treatment of acute clotting events involved in heart attack and stroke, and the treatment of atherosclerosis. Imaging: fluorescent or radiopaque agents to detect clots and atherosclerotic lesions or image tumors. This system has been used to successfully image clots, atherosclerosis, melanoma, breast cancer, prostate, lung and colon cancer. Management: John Muraski, Managing Director; Robert Davis, Managing Director

● ENTEROMEPrivate personalized medicine company dedicated to the development of drugs and biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine. Company has identified and patented biomarkers (originating from metagenomic signatures) associated with disease worsening or drug efficacy prediction. Intestines harbor an incredible number of bacteria, the gut microbiota, encoding 150-fold more genes (the microbiome) than their own genome. Each individual has his own personal and unique microbiota, with a large diversity between individuals. The contribution of the gut microbiota in health and diseases is undisputed, and recent studies demonstrated major alterations of the gut microbiota composition in patients with metabolic and inflammatory bowel diseases. Management: Pierre Belichard, CEO; Pierre Rimbaud, CMO

● EPIOMED THERAPEUTICSPrivate semi-virtual pharmaceutical organization engaged in the discovery and development of novel central nervous system (CNS) drugs, with a primary focus on anti-emetics, anxiolytics and performance sustainment agents. In October 2012, the Company entered into a Space Act Agreement with NASA and into collaborations with NASA and the U.S. Navy (NAMRU-D) for the development of INSCOP, a new quick-acting intranasal scopolamine formulation. Concurrent with the development for DoD acquisition, the company will work with the FDA to move INSCOP into civilian applications for motion sickness and other indications. Management: David Helton, CEO, CSO; Ernest H. Pfadenhauer, COO

● EPION HEALTHLeveraging the power of mobile devices at the point of care to deliver interactive solutions to both patients and providers. Tablet provides mobile health applications and content using a cloud based application and content management solution. From patient check-in through check-out, company's tablet engages the patient and provide tools to enhance the patient/provider experience. Epion fully integrates with electronic health record and practice management systems to reduce administrative costs and increase efficiencies.Management: Joe Blewitt, CEO

● ETVIEW MEDICAL / (ETVW)ETView Medical Ltd. is a public company that has successfully combined airway management with continuous direct airway visualization for medical professionals. ETView’s patented single-use single- and double-lumen tubes consist of a ventilation tube with an integrated continuous high-resolution video imaging system. The company has distribution agreements in North America, South America, Europe, Asia, and Africa. The VivaSight platform products are extensively protected by both US and international patents, both issued and pending, and have received US (FDA), European (CE), and Asian (KFDA, AMAR and others) regulatory clearances. Management: Bill Edelman, CEO; Yonat Granot, COO; Ronen Koyfman, CFO

● EXTHERA MEDICALExThera Medical is targeting the clinical treatment of blood-borne diseases including bacteremia and sepsis, as well as the removal of harmful substances present in banked human blood and/or caused by contact with man-made materials during cardiopulmonary bypass, dialysis and other extracorporeal procedures. Their propritearty product Seraph™ is used to treat strep. Later, Seraph may become a treatment for other bacteremias and viremias in a much wider patient population. Seraph™ consists of a specially designed cartridge packed with bioactive microspheres that create an adsorption-type hemofilter. Management: Rick Hughes, President; Joost van den Heuvel, CFO; Paul Smits, COO

● FIBROCELL SCIENCE / (FCSC)Fibrocell Science Inc. develops personalized autologous cell therapies for aesthetic, medical, and scientific applications. The company's lead product, LAVIV™ (azficel-T), is the first and only personalized aesthetic cell therapy approved by the FDA for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. The Fibrocell Science patented process involves the extraction of a patient's own natural fibroblasts, cells that contribute to the formation of connective tissue fibers, from a small sample of cells behind the ear and then being multiplied, purified, cryopreserved, and re-injected throughout multiple treatment sessions. These matrix fibers harbor regenerative effects such as improved skin texture, collagen secretion, and wound healing. This later-stage biotechnology company is planning to continue studies for additional aesthetic and therapeutic indications for azficel-T, and is collaborating with UCLA in its research. Management: David Pernock, Chairman & CEO; Declan Daly, Chief Operating Officer and Chief Financial Officer

● FLUOROPHARMA / (FPMI)FluoroPharma Medical, Inc. is a biopharmaceutical company engaged in the discovery and development of positron emission tomography (PET) imaging products. The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes. FluoroPharma is advancing two novel imaging products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease and agents that could potentially be used for imaging specific cancers. The market for molecular imaging agents currently exceeds $1.7billion annually and promises rapid growth for the foreseeable future. Patents related to FluoroPharma's portfolio of imaging compounds is robust. Management: Thijs Spoor, Chairman, CEO and President; Boyan Goumnerov, MD, COO; Tamara Rhein, CFO

18

● GLYSUREMedical device company that develops and distributes a system to monitor assist in the diagnosis of glucose related blood illnesses.The GlySure System comprises two main parts, a monitor and a sterile sensor set which includes an integrated fiber-optic sensor/introducer and a fully automated calibration module. The sensor is placed in intensive care patients via a central venous catheter (CVC). As central venous access is required on nearly all ICU patients, the sensor does not require any additional access lines.Management: Christopher Jones, CEO; Barry Crane, CTO; John Bradshaw, CFO

● HISTOGENICSHistogenics is a late-stage, privately held regenerative medicine company. The company combines cell therapy and tissue engineering technologies to develop innovative products for tissue repair and regeneration. The Company’s flagship products focus on the treatment of patients with active lifestyles who suffer from articular cartilage-derived pain and immobility. It has been named to the FierceMedicalDevices “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies of 2012. Management: Patrick T. O'Donnell, President and CEO; Kevin McArdle, CFO

● HISTOSONICSHistoSonics was founded to develop Histotripsy, a non-invasive ultrasound tissue ablation modality that mechanically homogenizes target tissue, resulting in complete cellular destruction within the target zone. The liquefied tissue is absorbed or voided without remnants or scarring. As a non-thermal modality, Histotripsy ablates tissue with NO THERMAL INJURY. HistoSonics developed its VORTX RX® platform for treatment of Benign Prostatic Hyperplasia (BPH). The VORTX RX Histotripsy system integrates Histotripsy tissue ablation with state of the art ultrasound imaging and procedure planning and tracking software. Because the treatment is non-thermal, there is very little inflammation and tissue margins are very clean, resulting in rapid recovery. These significant advantages were verified in extensive preclinical studies.Management: Tom Davison, Ph.D., Chairman and CEO; Christine Gibbons, President/COO; Jim Bertolina, Ph.D., VP R&D/CTO

● IMMUNE PHARMACEUTICALSImmune Pharmaceuticals, a privately held Israeli company, and EpiCept Corporation (“EpiCept”) (NASDAQ OMX Stockholm Exchange and OTCQX: EPCT) have entered into a definitive merger agreement on November 8th, 2012. The transaction is anticipated to close during the first quarter of 2013. The combined company, to be named Immune Pharmaceuticals, Inc. (“Immune Pharmaceuticals”), will be primarily focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. Immune’s lead product candidate, bertilimumab, is a full human monoclonal antibody that targets eotaxin-1, a chemokine involved in eosinophilic inflammation, angiogenesis and neurogenesis. Immune is currently initiating a placebo-controlled, double-blind Phase II clinical trial with bertilimumab for the treatment of ulcerative colitis. The companies’ collective oncology portfolios comprise: Immune’s NanomAbs®, a new generation of antibody drug conjugates, and EpiCept’s vascular disruptive agents. Immune Pharmaceuticals will continue efforts to secure a partner for EpiCept’s Phase III clinical development candidate AmiKet™, for which efficacy has been demonstrated for the treatment of chemotherapy-induced neuropathic pain and post-herpetic neuralgia. Management: Daniel Teper, CEO, Marc Rotherberg, CSO; Suzy Jones, Serge Goldner, CFO

● IMMUNOVACCINE TECH. INC. / (IMV.V)Immunovaccine Inc., a clinical stage vaccine company, applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The company’s DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase I human clinical trials. The company is also advancing a broad infectious disease pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with PfizerAnimal Health.Management: John Trizzino, President and CEO

● IMPLANDATA OPTHALMIC PRODUCTSPrivate medical device start-up, located in Hannover, Germany. The venture capital funded company owns the most superior and robust technology for wireless intracorporal pressure measurement. Implandata Ophthalmic Products GmbH will transform glaucoma care via dramatically better disease information at significant less effort. The system consists of an implantable micro sensor, responsible for pressure sensing and an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage. The company's technology has been broadly validated and the company’s first product is processed for getting regulatory CE mark approval, followed by FDA approval. Management: Max G. Ostermeier, Co-Founder, General Manager

● INFOBIONICEmerging medical device company founded in March 2011 with headquarters at The Massachusetts Medical Device Development Center (M2D2) on the campus UMass - Lowell. The company is developing the MoMeTM system a wireless remote monitoring platform for chronic disease with an initial market focus on the diagnosis and monitoring of cardiac arrhythmias. Their vision is to be part of the transformation of healthcare delivery by providing anywhere, anytime access to cardiac event monitoring with higher quality event detection, clinical efficacy and lower cost SaaS business model. Management: Nancy Briefs, Chairman & CEO ; Ravi Kuppuraj, Phd, CTO

● INNARA HEALTH "Series B" stage medical device company focused on developing and

commercializing products that are used by neonatal healthcare providers to assess and treat the problem of incompetent feeding in premature infants. With over 500,000 infants born prematurely in the U.S. each year, and as many as half suffering from the inability to adequately breast or bottle feed, there is a compelling need for accelerating the healthy development of oral feeding skills. Delayed development leads to extended stays in the hospital neonatal intensive care unit, creating a substantial medical, economic, and emotional burden on hospitals, patients and their families. Management: Michael Peck, CEO

● INNOVA MEDICAL DESIGNEarly stage company that has developed a solution to alleviate needle pain associated with diabetes and the multiple daily patient lancings required for blood glucose testing and insulin injections. In addition the company has developed prototype products to relieve needle pain related to initiating intravenous lines, blood draws, injections and vaccines. Innova’s products are designed to improve patient compliance and provider productivity while lowering healthcare costs. For the diabetes product platform the product opportunity is significantly “de-risked” as demonstration device-disposable systems for lancing and injection pain relief have been successfully tested, trial conducted, core IP issued with CIP filed and 510K regulatory path determined. Reimbursement already exists in major global markets. Development time to final product and FDA approval is estimated to be 18 months. Management: Tim O'Malley, CEO; John Buske, CFO

19

● INTELGENX / (IGXT)Drug delivery company focusing on the development of novel, orally administered products based on its proprietary oral drug delivery technologies. The company has positioned itself as a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. For the pharmaceutical industry, drug delivery systems represent an opportunity to extend the market exclusivity and product lifecycle of drugs whose patent protection is nearing expiration. Their primary business strategy is to develop pharmaceutical products based upon their proprietary drug delivery technologies and license the commercial rights to companies in the pharmaceutical industry once the viability of a product has been demonstrated. In exchange for licensing rights to their products, they seek funding consisting of advance down payments, milestone fees, reimbursement for development costs, and royalties on sales. In addition, They receive a manufacturing royalty from their contract manufacturers for the exclusive right to manufacture their products. Their licensing partners are typically responsible for managing the regulatory approval process of the product with the United States FDA. Management: Horst G. Zerbe, Ph.D., President and CEO; Paul Simmons, AFCA, CFO

● INTERFACE BIOLOGICSPrivately held commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Their primary technology focus areas are anti-thrombogenic additives and programmable combination drug delivery devices. IBI has licensed its Endexo™ anti-thrombogenic additives to AngioDynamics (Nasdaq: ANGO) for certain vascular access devices and Fresenius Medical Care (NYSE: FMS) for chronic dialysis systems. AngioDynamics BioFlo™ PICC with Endexo technology received FDA approval in August of 2012. IBI is actively seeking additional OEM licensing opportunities for blood contacting medical devices where reduced thrombosis, decreased platelet loss and/or lower heparin requirements are important. IBI is also working on developing branded or co-branded combination drug delivery devices in cardiology, orthopedics and urology. Management: Thomas P. Reeves, President & C.E.O.; Paul Santerre, Ph.D., CSO

● INVION / (IVX)Invion Limited is a clinical-stage drug development company that targets chronic inflammation. Focused on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus, Invion has two phase II proprietary therapeutic candidates: INV102 (nadolol) – a repurposed beta adrenergic inverse agonist; and INV103 (Ala-Cpn10) – a modified natural immunomodulator. INV102 (as nadolol) has been used in more than 8 million people for the treatment of high blood pressure, migraine and chest pain. Invion is now targeting INV102 for new indications. To date, two phase II clinical trials of INV102 have been completed which have demonstrated acceptable safety as well as dose-related activity showing a reduction of airway hyper-responsiveness. Two further phase II trials are due to commence. The larger of these trials, a phase II $4.4 million study in asthma patients, is being funded by the US National Institutes of Health (NIH). INV103 (Ala-Cpn10) is a potential new anti-inflammatory biologic therapeutic. In clinical trials carried out to date, Ala-Cpn10 has demonstrated signs of biological activity, including a reduction in disease-relevant pro-inflammatory cytokines. After a successful pre-IND meeting in December 2012, Invion is due to submit an IND application for the use of INV103 as a drug for the treatment of systemic lupus erythematosus in early 2013. Management: Dr Mitchell Glass, Executive Vice President R&D and Chief Medical Officer; Dr William Garner, Managing Director and CEO

● IR2DXIR2Dx 's novel diagnostic tests enable physicians to greatly improve detection and outcome for patients developing or suffering from diabetes, atherosclerosis, and related diseases. They are the leader tying together patient condition, test results, and treatment guidance in this field. IR2Dx tests enable effective treatment of the causes, stopping or delaying disease, and are used for all stages of disease, from prediabetes to late stage diabetes. Management: Robert Maurer, Founder/Chairman/CEO

● ISTO TECHNOLOGIESPrivate company developing innovative cartilage and bone regeneration products for spinal therapy, sports medicine and trauma. They specialize in Orthobiologics, Medical Device, Products for Spine and Orthopedics, Cell-Based Pipeline, Injectable Cell Therapy, Regenerative Medicine, Minimally Invasive Spine and Orthopedic Solutions, Living Cartilage Implants, Spinal Disc Regeneration. Since inception in 1997, ISTO has raised approximately $45 million to fund its research and development efforts. The Company’s major shareholders include Alafi Capital, LLC; Zimmer Holdings, Inc.; Ascension Health Ventures; Mid-America Transplant Services and Life Sciences Partners, B.V. Management: Mitch Seyedin, President and CEO; Scott Gill, CFO

● ITI HEALTHCharlottesville, VA-based biotechnology spin-out of the University of Virginia and Massachusetts General Hospital/Harvard Medical School. iTi is an acronym for “identify target image” which describes the company’s core capability to identify high‐value markers of disease as well as companion targeting agents, capable of delivering diagnostic and therapeutic payloads. An extensively validated lead program centers on a novel protein target, which is up-regulated specifically in pancreatic cancer, as well as in a growing list of malignancies. Pancreatic cancer is the 4th deadliest cancer with a prognosis (less than 6%, 5-year survival) that hasn’t changed in 40 years. Using proprietary targeting agents, multiple product opportunities have emerged addressing the pancreatic cancer diagnosis and therapy markets, each possessing significant unmet medical need. The lead product suite includes a preclinically-advanced imaging diagnostic (IND-cleared) and a promising therapeutic payload delivery system. The iTi developed pancreatic cancer imaging test will be a first-in-class, targeted imaging agent for detection of the disease. It has the potential to transform the diagnostic standard-of-care and enable early detection of tumors where the disease is potentially curable. iTi began operations in Q3-2011 and is financed with a seed equity investment round as well as three SBIR awards from the National Cancer Institute. Management: Greg Fralish, PhD CEO; Kimberly Kelly, PhD CSO; Colin Rolph, CFO.

● MEDOMICSMEDomics provides Mutation Expert-based Diagnosis (“MED”) of patients’ genome data to enhance personalized medicine through the employment of bioinformatics, clinical genetics, and mutation. MEDomics is recognized as the first lab focused on CLIA Next Generation (NextGen) sequencing for personalized medicine. Testing involves NextGen sequencing, confirmation of clinically important variants by Sanger sequencing, bioinformatics and interpretation. Its services include co- experimental design and wet bench, bioinformatics, post-bioinformatics interpretation, and manuscript co-preparation services. The company also provides diagnosis of mitochondrial diseases. It serves academia, pharmaceutical discovery and development, agri business, and veterinary medicine sectors. Management: Chairman; Steve Sommer, MD, PhD, President and CMO; Nicolas Nickelmann, PhD, COO; Craig Camp, MBA, CFO

20

● MEDTRONIC NEUROMODULATION / (MDT)Medtronic, is a company engaged in the medical technology for alleviating pain, restoring health, and extending life for people with chronic conditions worldwide. Medtronic develops and manufactures a range of products and therapies providing a continuum of care to diagnose, prevent and monitor chronic conditions. On January 13, 2011, the Company acquired Ardian, Inc. On February 25, 2011, the Company acquired Jolife, a privately-held company. In August 2011, the Company acquired PEAK Surgical, Inc. and Salient Surgical Technologies, Inc. Management: Omar Ishrak, Chairman and CEO; Gary Ellis, Senior Vice President and CFO

● MERCATOR MEDSYSTEMSMercator MedSystems, Inc., a private medical device and therapeutic solutions company, has developed a broad‐based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant and intractable medical conditions. The Company utilizes its novel and proprietary family of FDA 510(k)‐cleared Micro‐Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The Company's Cricket™ and Bullfrog® Micro‐Infusion Catheters are the first vascular‐access systems able to deliver drugs, genes, and cells safely and non‐systemically, through vessel walls into deep tissues.Management: Thomas M. Loarie, Executive Chairman; Kirk Seward, Co‐Founder,President, CTO

● METABIOMICSMetabiomics is an early stage molecular diagnostics company that is developing a non-invasive screening test for earlier and more accurate detection of colon polyps and colorectal cancer (CRC) based on human microbiome biomarkers and next-generation DNA sequencing technology. The novel, accurate (97% sensitivity), and extremely cost-effective approach has the potential to dislodge colonoscopy as the gold-standard for CRC screening, and to dramatically reduce the burden of CRC in terms of healthcare costs, morbidity and mortality. Management: Dr. Thomas J. Kuehn, VP and Chief Scientist: Dr. Patrick Gillevet

● MICRO INTERVENTIONAL DEVICESMicro Interventional Devices (MID) is an early stage medical device company that designs, manufactures and commercializes disruptive technologies for use in percutaneous and minimally invasive structural heart repair procedures. Their proprietary technology is based on a breakthrough in soft- tissue anchoring and associated delivery devices that enable off-pump procedures. Permaseal™ is a novel transapical access and closure device that combines soft -tissue anchors with advanced biocompatible elastomers to provide spontaneous wound closure after structural heart repair procedures, such as transcatheter aortic valve replacement (TAVR).Management: Michael P.Whitman, CEO: Willard Hennemann, PhD, CSO

● MIMEDX GROUP / (MDXG)Develops regenerative biomaterial products and bioimplants processed from human amniotic membrane. Biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and their tissue technologies, AmnioFix® and EpiFix®. Their tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through their donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx® is the leading supplier of amniotic tissue, having supplied over 100,000 implants to date to distributors and OEMs for application in Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors. Management; Parker H. "Pete" Petit, Chairman of the Board and CEO; William C. Taylor, President and COO; Michael J. Senken, VP and CFO

● MIRACOR MEDICALMiracor Medical Systems GmbH is a private cardiology company developing and commercializing a new technology called Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO®) to improve outcomes in acute coronary syndrome, heart failure, and cardiac surgery patients.The PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) technology is used after PCI/stenting. The technology does not interfere with door-to-balloon time and is applied from the venous side thereby reducing bleeding complications. The technology redistributes flow into the ischemic heart tissue clearing the microcirculation and revitalizes the heart tissue (myocardium) after a heart attack. The Company has secured a broad Intellectual Property (IP) position with 8 patents granted and other patents pending covering several markets segments and a methodology patent in the US.Management: Jon Hoem, CEO; Ludwig Gold, CFO/COO

● MONTERIS MEDICAL, INC.Monteris Medical Corporation is a privately held medical device company dedicated to the development of minimally invasive, MRI-guided neurosurgical solutions. They strive to provide options for surgeons treating brain cancer. In May 2012, they received $9M in Venture Round funding.Management: John Schellhorn, President & CEO; Rob Davidson, Vice President, Finance & CFO

● NANOVIRICIDES / (NNVC)NanoViricides Inc. is a pre-clinical public biotech company that develops drugs to combat viral infections. The company designs “nanoviricides” that fool viruses into attaching to them in that same way that viruses typically attach to the receptors on a cell surface. The company has drug candidates against HIV, seasonal influenzas and bird flu, herpes, viral eye diseases, and dengue viruses, and has nominated a clinical candidate in its FluCide™ program. The company has had patents issued in 25 countries thus far. Management: Eugene Seymour, MD, CEO; Anil Diwan, PhD, Chairman

● NEOCONTROLNeoControl is a privately held medical device company. developed a novel non-invasive neuro-muscular stimulator of the pelvic floor (called

“Neocontrol”), as a treatment for a variety of disease states. The Company has multiple patents approved, pending, and in preparation.NeoControl provides a non-surgical, non-invasive therapy for treatment of urinary and feces incontinence, incontinence after radical prostatectomy, pelvic pain, erectile dysfunction and other sexual disturbances, hemorrhoids, vagina tonus and more. NeoControl can offer unique therapeutic benefits. Unlike any other therapy, NeoControl exercises all the muscles of the pelvic floor to rebuild strength and endurance, reestablishing bladder control.Management: Dr. Michael Jordan, CEO

● NEUROMETRIX / (NURO)Develops and markets home use and point-of-care devices, associated consumables, and support software for the treatment and management of diabetes and its complications. The company is focused on diabetic neuropathies. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling chronic pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company’s products are used by physicians and other clinicians in retail health settings such as pharmacies, and by managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat® DPNCheck™ device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company has also begun to market the SENSUS Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company has additional therapeutic products in its pipeline. Management: Shai N. Gozani, CEO; Thomas T. Higgins, CFO

21

● ORAGENICS / (ORNI)Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation Inc., a synthetic biology company. The collaboration will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics which will work against resistant strains of bacteria. Oragenics also develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in over 13 countries worldwide.Management: John N. Bonfiglio, CEO; Michael Sullivan, CFO

● OXYGEN BIOTHERAPEUTICS / (OXBT)Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body that are deprived of oxygen. The company’s lead product candidate is Oxycyte PFC emulsion for traumatic brain injury, stroke and decompression sickness. Oxycyte is in Phase II-b trials in Switzerland and Israel as a treatment for severe Traumatic Brain Injury. The company also sells two cosmetic products under the DERMACYTE brand name: One is a concentrated spot treatment for facial lines, wrinkles and the other is a lower-concentration Eye Complex for the contour around your eye. Management: Michael B. Jebsen, CFO, Interim CEO & President.

● PRESSURE BIOSCIENCES / (PBIO)Public company using rapid cycles of hydrostatic pressure between ambient and ultra high levels to control biomolecular interactions, allowing for a high degree of precision, reproducibility, convenience, speed, and safety. This unique, patented technology offers the potential for broad applications in a number of established and emerging fields, including genomics, proteomics, drug discovery & development, process purification, pathogen inactivation, immunodiagnostics, and DNA sequencing.PBI focuses on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. Management: Richard T. Schumacher, Founder, CEO

● RADISENS DIAGNOSTICSRadisens is developing a single device to test across multiple blood test categories – high sensitivity immunoassays, clinical chemistries and haematology (cell counting) – using a single drop of blood, with instant results. Management: Jerry O'Brien, CEO

● RESPONSE BIOMEDICAL CORP / (RBM)Response Biomedical Corp. is commercializing a new class of diagnostic with the world's only immunoassay platform that provides lab quality information in a matter of minutes, anywhere, every time. RAMP tests are commercially available for three cardiac markers used in the early detection of heart attack, environmental detection of West Nile virus, and biodefense applications including the detection of anthrax, ricin, smallpox, and botulinum toxin.

● RIDGE DIAGNOSTICSPrivate neurodiagnostic company that offers a proprietary first-in-class blood test for Major Depressive Disorder (MDD). The Company’s test for Major Depressive Disorder consists of serum measurements of key Biological Markers and a proprietary algorithm that generates a single result. The outcome or score, MDDScore™, provides an assessment of the likelihood of an individual having depression (Major Depressive Disorder, or MDD). The component Biological Markers represent key biological pathways that have been shown to contribute to the pathophysiology of depression. These biological markers are mapped onto a multi-dimensional hyperspace model to create hyperspace vectors that define the biomarker patterns suggesting major depressive disorder. Management: Lonna J. Williams, CEO; Director; Perry Renshaw, CMO

● SALVETIS Salvetis robotics is a revolutionary platform that advances surgical technology. It empowers surgeons to provide keyhole surgery beyond the limits of human capability, at a lower cost, whilst dramatically expanding the numbers of procedures that are performed daily. That is because it is the first robotics platform that acts, feels , and mimics skills of the world’s finest surgeon. And it does so whilst potentially saving healthcare providers billions of dollars per year. Salvetis purpose is to make keyhole surgery universally accessible to all’. Salvetis is headquartered at Cambridge in the United Kingdom.Management: Martin Frost, Chairman

● S.E.A. MEDICAL SYSTEMSS.E.A. Medical Systems Inc. is a private healthtech company that pioneers smart solutions for the safe manufacture, preparation, delivery, and disposal of intravenous and other liquid medications. The Company’s medical devices catch life-threatening IV drug errors before they harm patients. S.E.A. is also expanding the technology platform to additional healthtech applications such as counterfeiting and biopharma manufacturing. S.E.A has been supported by strategic funding, Series A investors including Quantum Technology Partners, New Biology Ventures, and private investors, and Series B investor JK&B Capital. Management: Michael J. Weickert, CEO and President; James W. Bennett, COO

● SOFT TISSUE REGENERATIONSoft Tissue Regeneration Inc. is the first to create a bioengineered matrix that completely regenerates the ACL. The product is called the L-C Ligament® for ACL reconstruction. It is a synthetic scaffold that stabilizes the knee and encourages the regeneration of ligament tissue and should result in faster, better healing and greater odds of making a full recovery. STR has also submitted a 510(k) application for soft tissue augmentation and rotator cuff repair device. Management: Joseph W. Reilly, President and CEO

● STROMA MEDICAL CORPORATIONStroma Medical is a late development stage cosmetic/ophthalmic medical device company. There are approximately 26 million people worldwide that wear colored contact lenses. Stroma uses a proprietary laser system to safely and effectively change the color of people's eyes from brown or hazel to blue or green. The Stroma procedure is non-invasive. In fact, other than the use of a small device to help keep the patient's eyelid open during the procedure and the application of a mild topical medication, there is little or no contact with the patient's eye. The patient sits in front of the Stroma laser, and his or her head is stabilized. The procedure is then repeated to treat the other eye. The company has completed scientific, animal and an intial proof of concept clinical study. The company is preparing for its pilot study in 2Q, 2013. The company has patents issued and pending. Management: Doug Daniels, CEO; Greg Homer, CSO

22

● SYNTHETIC BIOLOGICS / (SYN)Public biotechnology company focused on the development of synthetic deoxyribonucleic acid (DNA)-based therapeutics and disease-modifying medicines for serious illnesses. Its initial synthetic biologic product candidate is intended to treat pulmonary arterial hypertension (PAH) by delivering therapeutic DNA to the lungs of PAH patients and controlling long-term expression of such DNA via an oral daily pill. In addition, they have several small molecule clinical-stage programs. In this area Synthetic is developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS). TrimestaTM (oral estriol) is also being developed for the treatment of cognitive dysfunction in female MS patients. Management: Jeffrey Riley, CEO, President and Director; C. Evan Ballantyne, CFO

● TARGETED MEDICAL PHARMA / (TRGM)Publicly-traded biotechnology company that develops and sells prescription medical foods, used in the treatment of pain syndromes, obesity, hypertension, immune disorders, sleep and cognitive disorders. The company also distributes generic and branded pharmaceuticals to physicians, pharmacies and skilled nursing facilities. TMP has been awarded more than $733,429 in government grants for it research associated with pain, cognitive and sleep disorders. Randomized Double Blind Clinical Trials involving TMP’s products have shown that when certain Rx Medical Foods are used in conjunction with pharmaceutical agents, efficacy is improved and the negative side effects associated with the non-Medical Food pharmaceuticals are potentially reduced. Management: William Shell, M.D., CEO and CSO

● TENSYS MEDICALTensys Medical is a leader in the development and commercialization of continuous, non-invasive, hemodynamic monitoring systems. Without a single needle stick, the company's FDA approved and CE-Marked T-line technology is used today in the OR and ICU to provide a patient's real-time pulse pressure waveform and blood pressure. With the future addition of advanced hemodynamic parameters, Tensys is positioned to continue its leadership in the growing, non-invasive, hemodynamic marketplace. Management: Christopher Jones, CEO

● TIANYIN PHARMACEUTICALS / (TPI)Tianyin is a public, late stage pharmaceutical company that focuses on produces a wide range of products that are half over the counter and half prescription medications. Through the Company's indirect wholly owned subsidiary Chengdu Tianyin Pharmaceutical Co., Ltd. (Chengdu Tianyin), it is engaged in the development, manufacturing, marketing and sales of patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines and other pharmaceuticals in the People's Republic of China. It is manufacturing a range of 56 products, 23 of which are listed in the highly selective National Medical Reimbursement List (NMRL) and seven are listed in the Essential Drug List (EDL) of the People's Republic of China. Management: Dr. Guoqing Jiang, MD , Chairman, CEO; Dr. James J. Tong, CFO, CBO, CDO

● TISSUE REGENERATION SYSTEMSStart-up medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Their technology has been evaluated in several large animal studies with very promising long term results. They have conceptualized initial product offerings, completed all required bench and animal testing, and filed their first regulatory submissions to the FDA. Approval of these submissions will allow TRS to commercialize products in the United States and they expect to begin generating meaningful revenues in the next two to three years. Management: Jim Fitzsimmons, President and CEO

● TNI BIOTECH / (TNIB)TNI BioTech Inc. is a biotech company combating fatal diseases through the activation and mobilization of the body’s immune system using their patented immunotherapy. their products and technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS and autoimcmune diseases. They have been developing active and adaptive forms of immunotherapies. Their proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Their most advanced clinical programs involve immunotherapy that works by isolating a patient’s lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient’s lymphocytes are reinfused back into the patient where they combat and destroy tumor cells.Management: Noreen Griffin, Founder & CEO

● UE LIFE SCIENCESUE LifeSciences (UELS) commercializes effective, low-cost and easy-to-use breast cancer screening solutions suitable for diverse range of demographics and healthcare systems around the world. Early detection of breast cancer is a global challenge. Mammography led programs are increasingly facing clinical limitations, infrastructure related bottlenecks and cultural barriers. NoTouch BreastScan™ is a touch-less and radiation-free infrared imager developed at UE LifeSciences. It is now FDA cleared for adjunctive breast cancer screening, suitable for use in women younger than 50 years of age, women with dense breasts and women at high-risk for breast cancer.UE LifeSciences is also developing a hand-held technology called Intelligent Breast Exam (iBE) based on the IP licensed from Drexel University. In Aug 2012, the State of PA Health Department awarded UELS $878,000 to further the commercialization efforts including a validation study for this low-cost, ultra-portable sensor technology. Presenter: Mihir Shah, Davood Tashayyod. Management: Mihir Shah, Founder & CEO, Matthew Campisi, Co-Founder & CTO

● VACCINOGENVaccinogen is a late stage, private biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX®, the only immunotherapy for Stage II colon cancer. The company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for the production of OncoVAX® vaccine.Vaccinogen is also focused on discovering, developing and manufacturing fully human monoclonal antibodies for human clinical use. Its HumaSPECT antibody was one of the first to be widely approved for any clinical use worldwide. They are developing other products based on work in colon carcinoma, renal carcinoma and melanoma. Management: Michael G. Hanna, Jr., Ph.D., Chairman and CEO; Debra R. Hoopes, CPA, MBA, CFO

● VERTIFLEXVertiFlex is a private company dedicated to the advancement of minimally invasive solutions that resolve the pain of lumbar spinal stenosis (LSS). VertiFlex has developed a proprietary interspinous access platform for performing both indirect and direct decompression of the lumbar spine., called the Superion Interspinous Spacer System. The Superion ISS is the most advanced, least invasive interspinous spacer available, and has been implanted in over 1500 patients worldwide, receiving CE mark in 2007. Superion is currently enrolling patients in a pivotal IDE clinical trial in the U.S. The company’s goal is to establish Superion as the standard of care for percutaneous treatment of lumbar spinal stenosis.It is backed by several sources including the venture capital firm, NEA.Management: Earl R. Fender - President and CEO; Jeff Swiecki, CFO

23

6th Annual OneMedForum Schedule

Tuesday - Janruary 8th Visit the website for Agenda/Schedule details.

24

6th Annual OneMedForum Schedule

Wednesday- January 9th Visit the website for Agenda/Schedule details.

25

6th Annual OneMedForum WorkshopsThe OneMedForumSF2013 workshops are designed to provide a unique opportunity for conference delegates to meet experts capable of meeting focused information of needs related to building a healthcare, medical technology or life science company. Workshops are small in size, highly focused, and interactive.

Topics covered will include: How does the new IPO on-ramp actually work? What are its benefits? Are there any downsides to taking advantage of the on-ramp? What additional research can now be published around an IPO? How can analysts have more time with investors under the bill? What are the Regulation A changes and when will they be effective? What will be the advantages and disadvantages of a Regulation A IPO? Does the JOBS Act have any benefits for companies that went public before the law? How are reverse mergers more attractive after the JOBS Act?

David N. Feldman Partner of Richardson & Patel His practice focuses on corporate and securities matters and general representation of public and private companies, investment banks, private equity firms and high net worth individuals. He also actively advises on mergers and acquisitions and private equity, debt, venture capital and other financings. David is considered one of the country’s leading experts on alternatives to traditional initial public offerings, including reverse mergers, in which a private company becomes publicly traded through a merger with a publicly held “shell” company.

Nimish P. PatelJD/MBA/CPACo-founder and managing partner at Richardson & Patel, LLP. Mr. Patel’s primary focus is corporate and securities laws and is well versed in drafting complex business transactional documents. Mr. Patel’s experience includes mergers and acquisitions for private and public companies, angel and venture capital financing, IPOs, Secondary Offerings, PIPEs, and other financing and corporate restructurings.

Going Public After the JOBS Act.Changes to Sarbanes-Oxley, changes to Regulation A, and the IPO on-ramp.

Tuesday, January 8th9:45AM – 10:45AM

26

This workshop will explore public, private, and other forms of reimbursement opportunities that are key to commercial success in this healthcare reform environment. We will explore the attributes of successful reimbursement due diligence, payer segmentation, and the opportunities and challenges from healthcare reform. We will also discuss trends on ways investors are leveraging reimbursement and market access data for valuation considerations and financing.

Thomas BarkerPartner, Foley Hoag LLPThomas Barker joined Foley Hoag in March 2009. Thomas focuses his practice on complex federal and state health care legal and regulatory matters with a special expertise in Medicare and Medicaid law and regulations. Prior to joining the firm, he was acting General Counsel at the U.S. Department of Health and Human Services (HHS) and General Counsel of the Centers for Medicare & Medicaid Services (CMS). Since arriving at Foley Hoag, Thomas has focused his practice on Medicare and Medicaid reimbursement issues for innovator pharmaceutical products; provided legal, regulatory and strategic advice for multiple Medicare and Medicaid providers.

Bruce QuinnMD Ph.D., Senior Health Policy Advisor, Foley Hoag LLPBruce Quinn, MD Ph.D., is a national expert on Medicare policy, the impact of health reform on innovation and the crafting of successful business strategies within the U.S. healthcare reimbursement system. Dr. Quinn has worked successfully with both large and small companies in overcoming hurdles to commercialization through negotiation, understanding insightful ways to use the existing system to advantage and the mechanisms of policy change. Since 2008, he has been a full time business strategist working with attorney and policy teams for healthcare and life sciences clients in the firm’s Government Strategies practice.

Reimbursement and Payer Engagement Strategies for Market Access + Financing Success.

Tuesday, January 8th11:10AM - 12:00PM

Attributes of successful reimbursement and the challenges from healthcare reform.

27

This session features three CEO’s currently involved with companies that are commercialized in Europe. This interactive roundtable is designed to cover main themes for product growth in Europe, as well as an analysis of particular key developmental milestones. Topics explored include:

• Strategy: Why Europe today — Market Expectations, and how to navigate cost, time and resources• Financial: Creative Funding, the best use of resources in today’s market, and realistic objectives• Regulatory: Clinical trials, key opinion leaders, geography, and time to market• Reimbursement: Where and when, time savers, and navigating the system

The workshop will also explore short-term milestones upon commercialization.

Rick HughesPresident, HealthLink EuropeHas been in the medical device industry for 18 years, and joined HealthLink Europe in February 2005. During the first year of his tenure, HealthLink Europe secured funding from a private investment firm, opened a North American Office, and invested in top quality management and IT systems, to support the future growth of the company. Mr. Hughes became President of HealthLink Europe in December 2005 and since then the company has grown significantly each year.

Greg LambrechtFounder and Executive Directorof Intrinsic Therapeutics, Inca venture-backed medical device company focused on addressing the needs of patients with spinal disorders. Mr. Lambrecht is also founder and board member of Viacor, Inc., a start-up medical device company, and Coravin, LLC, a consumer product company, both in the Boston area. Lambrecht also held various management positions in product development, marketing, and business development within Pfizer’s Medical Technology Group.

Gibb ClarkeCo-founder and CEO of Blockade MedicalHas more than 10 years experience as a medical device executive with a specific focus on new technology development for the interventional neurovascular marketplace. Prior to co-founding Blockade, Gibb co-founded Pulsar Vascular, Inc. in 2006. A novel therapeutic approach for challenging and complex cerebral aneurysms.

Paul GeudensFounder and CEO of Quarterback ConsultingQuarterback Consulting’s mission is to provide executive support to US based Cardiovascular Device startups in their (pre)-commercialization into Europe, the latest being Surpass Medical that was recently acquired by Stryker for $135M. Paul is a senior executive holding a unique blend of medical, commercial and business development experience. Paul started his career in ’81 as head of the Department of Interventional Cardiology at the University Hospital of Antwerp, Belgium.

Tuesday, January 8th2:15PM – 3:10PMOvercoming the

Challenges of Commercializing in Europe.Case studies with industry leaders exploring regulatory, market opportunity and creative financing.

28

The first part of the workshop will elucidate the new and changing Life Science Investor universe. The workshop will clearly identify and explain the ten categories of Life Science Investors. Specific examples will be provided of current real world investor mandates which will give insight into specifically what investors are seeking. The second part of the workshop will be a tactical session of how to identify and go after likely investor candidates. This will include discussions on creating a Global Target List (GTL) of Investors that are a fit for your particular product or service segment and your particular company stage of development.

Dennis FordCEO, Life Science NationFounder and CEO of Life Science Nation (LSN). He has spent his career launching new companies and developing markets for nascent game-changing technologies. Dennis has distinct value in understanding the world of global alternative investors and how that relates to high-growth, early-stage technologies. Dennis’s is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process.

Max KlietmannVP of Investor Research,Life Science NationManages all research functions at LSN, managing LSN’s data team’s senior global research analysts and the data validation teams. LSN has over 24,000 active life science company profiles and 6,000 life science investor profiles. Carlisle & Company, Associate Consultant – Worked on projects internationally for several global manufacturers and private equity firms in the areas of M&A due diligence, strategy initiatives, and other data-intensive projects

Tuesday, January 8th3:30PM – 4:30PMFundraising in the

Life Science Arena.What do investors look for in contemporary valuation?How has a new class of investors in the space altered traditional strategy?

29

This workshop will explore public, private and other forms of financing opportunities in this economic environment. We will explore the attributes of successful public financings, and the types of opportunities available to enter the public markets. We will also discuss trends in private financings including the preparatory process, valuation considerations and establishing reasonable expectations. The workshop will also comment on other types of financing vehicles.

Shoshannah D. KatzPartner, K&L GatesMs. Katz practices in the areas of securities, mergers and acquisitions, finance and general corporate matters, focusing on providing day-to-day client support and coordination of governance issues, transactional needs and specialty counsel. She advises private and public companies in connection with raising capital and issuing securities, compliance with corporate and securities laws and corporate governance practices, debt financing, and negotiation and documentation of a wide variety of corporate and commercial transactions.

John PennettPartner, Eisner AmperJohn Pennett is the Partner-in-Charge of the Life Sciences Group and Technology Group. He has more than 25 years of public accounting experience with a strong emphasis on public and private life sciences companies. John is a frequent writer and speaker on topics related to issues impacting businesses in the life sciences and technology space. He is the publisher of Catalyst, a magazine focused solely on issues related to life sciences and pharmaceutical companies. John also serves on the firm’s Public Companies Group.

Financing Strategies for Today’s Turbulent and Risk Adverse Markets.

Wednesday, January 9th8:50AM - 9:40AM